ArticleClinical epigenetics2018
Correction to: Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Article in Clinical epigenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 68 citations in OpenAlex.
- Application of parametric survival analysis to women patients with breast cancer at Jimma University Medical Center.BMC cancer · 2023Article
- Synergistic effects of combined cisplatin andJournal of Taibah University Medical Sciences · 2023Article
- Profiling non-coding RNA levels with clinical classifiers in pediatric Crohn's disease.BMC medical genomics · 2021Article
- Interleukin‑6 signalling as a valuable cornerstone for molecular medicine (Review).International journal of molecular medicine · 2021Review
- TP53-Activated lncRNA GHRLOS Regulates Cell Proliferation, Invasion, and Apoptosis of Non-Small Cell Lung Cancer by Modulating the miR-346/APC Axis.Frontiers in oncology · 2021Article
- LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1.Oncogene · 2020Article
- Review
- LncRNA DHRS4-AS1 Inhibits the Stemness of NSCLC Cells by Sponging miR-224-3p and Upregulating TP53 and TET1.Frontiers in cell and developmental biology · 2020Article
- Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico.Oncology letters · 2019Article
- LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2.Frontiers in oncology · 2019Article
- LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.Cell transplantationArticle
Corrections and comments
- Erratum for
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upon publication of the original article [1], the authors noticed that the Figs. 1, 2 and 3 were incorrectly given.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.